The capacity of miR-483-5p to counteract TAU pathology by blocking ERK1/2-mediated TAU phosphorylation is contextualized by the enrichment of miR-483-5p in the brain [32] and in still higher quantities in AD patients [17]. This evidence concerns the gene MAPK3 and Alzheimer disease.